{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:19:13Z","timestamp":1791908353844,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T00:00:00Z","timestamp":1534118400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030-159999"],"award-info":[{"award-number":["310030-159999"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01865","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T03:32:22Z","timestamp":1534131142000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1"],"prefix":"10.3389","volume":"9","author":[{"given":"Aleksandra Maria","family":"Dufour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Chizzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.rdc.2007.11.002","article-title":"Fibrosis in systemic sclerosis","volume":"34","author":"Varga","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.autrev.2010.09.016","article-title":"Fibrosis and immune dysregulation in systemic sclerosis","volume":"10","author":"Chizzolini","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1684\/ecn.2013.0325","article-title":"T cell abnormalities in systemic sclerosis with a focus on Th17\u2009cells","volume":"23","author":"Brembilla","year":"2012","journal-title":"Eur Cytokine Netw"},{"key":"B7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor beta \u2013 at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.5301\/jsrd.5000258","article-title":"Contribution of interleukin-6 to the pathogenesis of systemic sclerosis","volume":"2","author":"Kawaguchi","year":"2017","journal-title":"J Scleroderma Relat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1089\/wound.2017.0732","article-title":"Toll-like receptor-4 signaling drives persistent fibroblast activation and prevents fibrosis resolution in scleroderma","volume":"6","author":"Bhattacharyya","year":"2017","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17 production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B13","first-page":"765","article-title":"Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis","volume":"27","author":"Meloni","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jdermsci.2008.01.001","article-title":"Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?","volume":"50","author":"Murata","year":"2008","journal-title":"J Dermatol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e5903","DOI":"10.1371\/journal.pone.0005903","article-title":"The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes","volume":"4","author":"Radstake","year":"2009","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/art.30159","article-title":"Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension","volume":"63","author":"Hsu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3486","article-title":"Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease","volume":"13","author":"Truchetet","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/art.37860","article-title":"Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement","volume":"65","author":"Truchetet","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/1756-185X.12290","article-title":"Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis","volume":"17","author":"Olewicz-Gawlik","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1186\/ar2821","article-title":"Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations","volume":"11","author":"Gourh","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.imlet.2017.09.007","article-title":"Is there a role for IL-17 in the pathogenesis of systemic sclerosis?","volume":"195","author":"Chizzolini","year":"2018","journal-title":"Immunol Lett"},{"key":"B22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1084\/jem.20092121","article-title":"Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent","volume":"207","author":"Wilson","year":"2010","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.4049\/jimmunol.1004081","article-title":"Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms","volume":"187","author":"Mi","year":"2011","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.4049\/jimmunol.1100591","article-title":"Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts","volume":"188","author":"Nakashima","year":"2012","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"H3356","DOI":"10.1152\/ajpheart.00928.2007","article-title":"IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1\/2-dependent C\/EBP-beta, NF-kappaB, and AP-1 activation","volume":"293","author":"Cortez","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1186\/ar4334","article-title":"Th17\u2009cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts","volume":"15","author":"Brembilla","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e105008","DOI":"10.1371\/journal.pone.0105008","article-title":"High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis","volume":"9","author":"Lonati","year":"2014","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ejcb.2008.01.012","article-title":"Integrins and the activation of latent transforming growth factor beta1 \u2013 an intimate relationship","volume":"87","author":"Wipff","year":"2008","journal-title":"Eur J Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/1523-1747.ep12874503","article-title":"Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis?","volume":"94","author":"Gruschwitz","year":"1990","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1006\/clin.1993.1170","article-title":"Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis","volume":"69","author":"Sfikakis","year":"1993","journal-title":"Clin Immunol Immunopathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/art.1780370218","article-title":"Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud\u2019s phenomenon","volume":"37","author":"Higley","year":"1994","journal-title":"Arthritis Rheum"},{"key":"B32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10067-003-0706-5","article-title":"The roles of transforming growth factor type beta3 (TGF-beta3) and mast cells in the pathogenesis of scleroderma","volume":"22","author":"Ozbilgin","year":"2003","journal-title":"Clin Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/jid.2009.318","article-title":"A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity","volume":"130","author":"Sargent","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.5301\/jsrd.5000265","article-title":"Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis","volume":"2","author":"Choy","year":"2017","journal-title":"J Scleroderma Relat"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.5301\/jsrd.5000266","article-title":"Interleukin-6 and related proteins as biomarkers in systemic sclerosis","volume":"2","author":"Denton","year":"2017","journal-title":"J Scleroderma Relat"},{"key":"B37","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","article-title":"Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via Gremlin protein","volume":"289","author":"O\u2019Reilly","year":"2014","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1038\/cti.2013.2","article-title":"Interleukin-6: a new therapeutic target in systemic sclerosis?","volume":"2","author":"O\u2019Reilly","year":"2013","journal-title":"Clin Transl Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am J Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1186\/ar4672","article-title":"Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis","volume":"16","author":"Desallais","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","article-title":"Interleukin-6 signaling drives fibrosis in unresolved inflammation","volume":"40","author":"Fielding","year":"2014","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B44","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1096\/fj.05-4870fje","article-title":"Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts","volume":"20","author":"Fineschi","year":"2006","journal-title":"FASEB J"},{"key":"B46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4049\/jimmunol.161.1.409","article-title":"Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines","volume":"161","author":"Chabaud","year":"1998","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.4049\/jimmunol.146.10.3437","article-title":"Transforming growth factor-beta regulation of IL-6 production by unstimulated and IL-1-stimulated human fibroblasts","volume":"146","author":"Elias","year":"1991","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"12933","DOI":"10.1074\/jbc.274.18.12933","article-title":"Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts","volume":"274","author":"Eickelberg","year":"1999","journal-title":"J Biol Chem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1096\/fasebj.13.15.2105","article-title":"Specificity, diversity, and regulation in TGF-beta superfamily signaling","volume":"13","author":"Piek","year":"1999","journal-title":"FASEB J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1101\/gad.14.6.627","article-title":"Controlling TGF-beta signaling","volume":"14","author":"Massague","year":"2000","journal-title":"Genes Dev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1523-1747.2002.01641.x","article-title":"Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation","volume":"118","author":"Verrecchia","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.2741\/2875","article-title":"Pathogenic role of CCL2\/MCP-1 in scleroderma","volume":"13","author":"Yamamoto","year":"2008","journal-title":"Front Biosci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12938","article-title":"The role of TGF-beta in Th17 differentiation","author":"Zhang","year":"2018","journal-title":"Immunology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","article-title":"IL-17 in chronic inflammation: from discovery to targeting","volume":"22","author":"Beringer","year":"2016","journal-title":"Trends Mol Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.5301\/jsrd.5000267","article-title":"Tocilizumab treatment of patients with systemic sclerosis: clinical data","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat"},{"key":"B58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.matbio.2017.12.016","article-title":"Targeting TGF-beta signaling for the treatment of fibrosis","author":"Gyorfi","year":"2018","journal-title":"Matrix Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T05:19:31Z","timestamp":1693804771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,13]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2018.01865"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01865","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,13]]},"article-number":"1865"}}